Metsera (NASDAQ:MTSR) Shares Down 4% – Time to Sell?

Metsera, Inc. (NASDAQ:MTSR)’s stock price was down 4% on Thursday . The stock traded as low as $28.20 and last traded at $28.68. Approximately 22,857 shares changed hands during trading, a decline of 96% from the average daily volume of 566,749 shares. The stock had previously closed at $29.86.

Analyst Upgrades and Downgrades

Several research analysts have commented on MTSR shares. Bank of America began coverage on shares of Metsera in a research note on Tuesday, February 25th. They set a “buy” rating and a $38.00 price objective for the company. Evercore ISI started coverage on shares of Metsera in a research note on Tuesday, February 25th. They set an “outperform” rating for the company. Guggenheim assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price objective on the stock. Finally, Cantor Fitzgerald initiated coverage on Metsera in a research report on Tuesday, February 25th. They set an “overweight” rating for the company.

Metsera Stock Down 6.7 %

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.